Testing a new drug VO659 for genetic neurodegenerative diseases

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This clinical trial aims to evaluate the safety and tolerability of the drug VO659 in patients with spinocerebellar ataxia types 1 and 3, as well as Huntington's disease. It is a first-in-human, open-label, multiple ascending dose trial that will assess the pharmacokinetics of the drug after intrathecal administration. Participants will be assigned to different dose cohorts based on their enrollment order, with a total trial duration of approximately 42 weeks. The study will focus on individuals with mild to moderate symptoms of these conditions, aiming to gather data on the drug's effects on disease progression.

Why it matters

Who can join: the full rules

Main Inclusion Criteria:

* Provide written informed consent (signed and dated). Patients should be assessed for their ability to give informed consent using the Evaluation to Sign Consent tool.
* Is ≥25 and ≤60 years of age inclusive, of any gender, at the time of signing the informed consent.
* Have SCA1, SCA3 or HD meeting one of the following criteria:

  1. SCA1 and SCA3: mild to moderate disease with a Scale for Assessment and Rating of Ataxia (SARA) score of ≥3 and ≤18
  2. HD: early manifest, Stage I disease with a Total Functional Capacity (TFC) Score of ≥11 and ≤13 and a Unified Huntington's Disease Rating Scale (UHDRS) Diagnostic Confidence Level (DCL) of 4.
* Have genetically confirmed disease, defined by increased cytosine, adenine, and guanine (CAG) repeat length in the disease-causing allele by direct DNA testing. For each indication the requirements are:

  1. SCA1: ≥41 contiguous, uninterrupted CAG repeats in the ATXN1 gene
  2. SCA3: ≥61 repeats in the ATXN3 gene
  3. HD: ≥40 CAG repeats in the HTT gene.
* Please note there will be additional inclusion criteria

Main Exclusion Criteria:

* Have any condition that would prevent participation in trial assessments.
* Have one or more pathogenic mutation(s) in another polyQ disease gene, i.e., ATXN2, CACNA1A, ATXN7, TBP, AR, and ATN1, plus either ATXN3 and HTT (for patients with SCA1), ATXN1 and HTT (for participants with SCA3), or ATXN1 and ATXN3 (for participants with HD), in addition to the disease-causing mutation in the ATXN1 (patients with SCA1), ATXN3 (patients with SCA3) or HTT (patients with HD) gene.
* Have clinical diagnosis of moderate or severe chronic migraines or history of the post-lumbar-puncture headache of moderate or severe intensity requiring hospitalisation or blood patch.
* Have a brain, spinal or systemic disorder that would interfere with the LP process, CSF circulation, or safety assessments.
* Have history of bleeding diathesis or coagulopathy, platelet count less than the lower limit of normal unless stable and assessed by the investigator and the Medical Monitor to be not clinically significant.
* Have uncompensated cardiovascular disorder, any past or present cardiac arrhythmia, QTcF values on screening ECG of \>470 ms, familial history of long QT syndrome or sudden unexpected death.
* Have a history of attempted suicide, suicidal ideation with a plan that required hospital admission and/or change in level of care within 12 months prior to screening.
* Have medical, psychiatric, or other conditions that, in the judgement of the investigator, may compromise the patient's ability to understand the patient information sheet, to give informed consent, to comply with all trial requirements, or to complete the trial.
* Prior treatment with an antisense oligonucleotide (including siRNA).
* Pregnant or breast-feeding (lactating) women or women who plan to become pregnant or breast-feed during the trial.
* Unable to undergo and tolerate MRI scans.
* Please note there will be additional exclusion criteria

Where it's running

• Rigshospitalet
  Copenhagen, Denmark Recruiting
• Centre Hospitalier Universitaire dÁngers
  Angers, France Recruiting
• CHU Gui de Chauliac Montpellier- Expert Center of Neurogenetic diseases, Department of Neurology
  Montpellier, France Recruiting
• Universtiry Hospitals Pitie Salpetriere - Charles foix - Paris
  Paris, France Recruiting
• Katholisches Klinikum Bochum
  Bochum, Germany Recruiting
• Deutsches Zentrum fur Neurodegenerative Erkrankungen (DZNE)
  Bonn, Germany Recruiting

Study contacts

• Study coordinator: Chief Medical Officer
• Email: info@vicotx.com
• Phone: +31 71 2036800

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Registry for patients with rare diseases

  This study is creating a central registry for people with rare diseases to help connect them with researchers and improve treatments.

  Recruiting Sanford Health · Sioux Falls, South Dakota · NCT01793168

• Natural history and genetic modifiers in spinocerebellar ataxias

  This study tests how spinocerebellar ataxias progress over time and whether other genes influence the disease.

  Recruiting at 15 sites National Ataxia Foundation · Los Angeles, California and 16 other locations · NCT01060371

• Pridopidine for Huntington's Disease: a 1-year, randomized, placebo-controlled study

  This trial tests whether pridopidine can slow the progression of Huntington's disease in adults compared with placebo over one year.

  Recruiting at 17 sites Phase 3 Prilenia · Birmingham, Alabama and 65 other locations · NCT07609108

• Low-intensity focused ultrasound targeting the globus pallidus to improve movement in Huntington's disease

  This trial tests whether different pulse frequencies of low-intensity focused ultrasound (LIFU) aimed at a deep brain target can safely reduce chorea and other motor symptoms in adults with Huntington's disease.

  Recruiting First Affiliated Hospital of Fujian Medical University · Fuzhou, Fujian · NCT07513844

• Safety and tolerability of human neural stem cell implants for Huntington's disease

  This research will test whether an implant of hNSC-01 human neural stem cells is safe and tolerable for adults with Huntington's disease.

  Recruiting Phase 1/2 University of California, Irvine · Irvine, California · NCT07451613

• SKY-0515 for adults with Huntington's disease

  This trial will test whether the oral drug SKY-0515 can lower harmful huntingtin protein and improve symptoms in adults aged 25 and older with genetically confirmed Huntington's disease.

  Recruiting at 19 sites Phase 2/3 Skyhawk Therapeutics, Inc. · Englewood, Colorado and 30 other locations · NCT07378644

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.